In a research report published today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Tetraphase Pharmaceuticals (NASDAQ:TTPH) with a $50 price …
In a research report sent to investors today this morning, Cantor analyst Daniel Brims reiterated a Buy rating on Tetraphase Pharmaceuticals (NASDAQ:TTPH) and raised …
Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Tetraphase Pharmaceuticals (NASDAQ:TTPH) with a $23 price target, which (surprisingly) represents a slight …
In a research report issued today, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on Tetraphase Pharmaceuticals (NASDAQ:TTPH) with a $23.00 price …
